Grove Bank & Trust’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $296K | Hold |
5,644
| – | – | 0.03% | 220 |
|
|
2026
Q1 | $311K | Buy |
5,644
+44
| +0.8% | +$2.38K | 0.04% | 211 |
|
|
2025
Q4 | $275K | Hold |
5,600
| – | – | 0.03% | 228 |
|
|
2025
Q3 | $242K | Hold |
5,600
| – | – | 0.03% | 231 |
|
|
2025
Q2 | $215K | Hold |
5,600
| – | – | 0.03% | 240 |
|
|
2025
Q1 | $217K | Sell |
5,600
-21
| -0.4% | -$769 | 0.03% | 230 |
|
|
2024
Q4 | $190K | Sell |
5,621
-455
| -7% | -$16.4K | 0.03% | 225 |
|
|
2024
Q3 | $248K | Sell |
6,076
-248
| -4% | -$10.1K | 0.04% | 202 |
|
|
2024
Q2 | $243K | Hold |
6,324
| – | – | 0.04% | 195 |
|
|
2024
Q1 | $271K | Hold |
6,324
| – | – | 0.05% | 187 |
|
|
2023
Q4 | $234K | Sell |
6,324
-140
| -2% | -$5.03K | 0.04% | 198 |
|
|
2023
Q3 | $234K | Sell |
6,464
-640
| -9% | -$22.7K | 0.05% | 196 |
|
|
2023
Q2 | $253K | Sell |
7,104
-557
| -7% | -$20K | 0.05% | 190 |
|
|
2023
Q1 | $273K | Sell |
7,661
-658
| -8% | -$23K | 0.06% | 184 |
|
|
2022
Q4 | $292K | Buy |
+8,319
| New | +$277K | 0.06% | 186 |
|
|
2022
Q3 | – | Sell |
-13,647
| Closed | -$743K | – | 212 |
|
|
2022
Q2 | $743K | Sell |
13,647
-2,118
| -13% | -$117K | 0.18% | 106 |
|
|
2022
Q1 | $858K | Sell |
15,765
-97
| -0.6% | -$5.27K | 0.17% | 111 |
|
|
2021
Q4 | $875K | Buy |
15,862
+2,400
| +18% | +$125K | 0.17% | 112 |
|
|
2021
Q3 | $643K | Sell |
13,462
-432
| -3% | -$21.7K | 0.14% | 128 |
|
|
2021
Q2 | $691K | Sell |
13,894
-7
| -0.1% | -$336 | 0.15% | 123 |
|
|
2021
Q1 | $620K | Sell |
13,901
-1,248
| -8% | -$56.6K | 0.15% | 122 |
|
|
2020
Q4 | $697K | Sell |
15,149
-3,221
| -18% | -$148K | 0.18% | 110 |
|
|
2020
Q3 | $865K | Sell |
18,370
-2,989
| -14% | -$150K | 0.26% | 88 |
|
|
2020
Q2 | $1.09M | Sell |
21,359
-1,114
| -5% | -$57.2K | 0.36% | 70 |
|
|
2020
Q1 | $1.06M | Buy |
22,473
+343
| +2% | +$18.3K | 0.42% | 63 |
|
|
2019
Q4 | $1.3M | Sell |
22,130
-959
| -4% | -$53.3K | 0.39% | 67 |
|
|
2019
Q3 | $1.23M | Buy |
23,089
+1,462
| +7% | +$75.2K | 0.4% | 66 |
|
|
2019
Q2 | $1.08M | Buy |
21,627
+425
| +2% | +$21.3K | 0.4% | 64 |
|
|
2019
Q1 | $1.11M | Buy |
21,202
+1,119
| +6% | +$55.9K | 0.42% | 58 |
|
|
2018
Q4 | $959K | Sell |
20,083
-519
| -3% | -$25.6K | 0.45% | 58 |
|
|
2018
Q3 | $1.03M | Sell |
20,602
-416
| -2% | -$21.1K | 0.42% | 62 |
|
|
2018
Q2 | $1.06M | Sell |
21,018
-209
| -1% | -$10.5K | 0.45% | 58 |
|
|
2018
Q1 | $1.04M | Buy |
21,227
+1,209
| +6% | +$56.3K | 0.46% | 58 |
|
|
2017
Q4 | $887K | Sell |
20,018
-1,080
| -5% | -$49.9K | 0.39% | 69 |
|
|
2017
Q3 | $1.07M | Buy |
21,098
+794
| +4% | +$40.3K | 0.52% | 47 |
|
|
2017
Q2 | $1.09M | Buy |
20,304
+1,110
| +6% | +$59.2K | 0.7% | 34 |
|
|
2017
Q1 | $1.01M | Sell |
19,194
-1,712
| -8% | -$86.8K | 0.83% | 30 |
|
|
2016
Q4 | $1.01M | Sell |
20,906
-704
| -3% | -$34.8K | 0.77% | 35 |
|
|
2016
Q3 | $1.17M | Buy |
21,610
+884
| +4% | +$48.5K | 0.99% | 28 |
|
|
2016
Q2 | $1.12M | Buy |
20,726
+1,476
| +8% | +$77.8K | 1.01% | 28 |
|
|
2016
Q1 | $976K | Buy |
19,250
+1,070
| +6% | +$53.3K | 0.89% | 32 |
|
|
2015
Q4 | $917K | Buy |
+18,180
| New | +$927K | 0.82% | 35 |
|
Other funds holding GSK
JEST
Grove Bank & Trust's GSK Position: Q2 2026 in Review
Grove Bank & Trust held its GSK (GSK) position steady in Q2 2026 at 5,644 shares worth $296K. The position accounts for 0.03% of the portfolio, ranked #220.
Grove Bank & Trust first reported a position in GSK in Q4 2015 and has held it in 42 quarters since. The position peaked at $1.3M in Q4 2019. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Grove Bank & Trust held 5,644 shares of GSK worth $296K as of Q2 2026.
- Grove Bank & Trust left its GSK share count unchanged in Q2 2026.
- GSK made up 0.03% of Grove Bank & Trust's portfolio in Q2 2026, its #220 holding.
- Grove Bank & Trust first reported a position in GSK in Q4 2015 and has held it in 42 quarters since.
- Grove Bank & Trust's GSK position peaked at $1.3M in Q4 2019.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Grove Bank & Trust's 13F filing for Q2 2026, filed 7 Jul 2026.